{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:29:11Z","timestamp":1789907351447,"version":"4.0.1"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T00:00:00Z","timestamp":1410912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Bioavailability of deferasirox (<jats:styled-content style=\"fixed-case\">DFX<\/jats:styled-content>) is significantly affected by the timing of administration relative to times and to composition of meals. Its elimination half\u2010life is also highly variable \u2013 in some patients as a result of gene polymorphisms. Understanding whether deferasirox plasma levels are related to specific characteristics of patients could help physicians to devise a drug regimen tailored the individual patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed deferasirox plasma concentrations (<jats:styled-content style=\"fixed-case\">C<jats:sub>DFX<\/jats:sub><\/jats:styled-content>) in 80 patients with transfusion\u2010dependent anemias, such as thalassemia, by a high performance liquid chromatography (<jats:styled-content style=\"fixed-case\">HPLC<\/jats:styled-content>) assay. We used a multivariate linear regression model to find significant associations between <jats:styled-content style=\"fixed-case\">C<jats:sub>DFX<\/jats:sub><\/jats:styled-content> and clinical\/demographical characteristics of patients. All patients were genotyped for <jats:italic><jats:styled-content style=\"fixed-case\">UGT<\/jats:styled-content>1A1<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010six patients were female, 24 were male, the great majority (88%) affected by <jats:italic>\u03b2<\/jats:italic>\u2010thalassemia, and 15 were children and adolescents. No statistical correlation was detectable between <jats:styled-content style=\"fixed-case\">C<jats:sub>DFX<\/jats:sub><\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DFX<\/jats:styled-content> dose (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.6). Age, time from last drug intake to blood sampling, and ferritin levels in the 6\u00a0months before study initiation were significantly and inversely associated with <jats:styled-content style=\"fixed-case\">C<jats:sub>DFX<\/jats:sub><\/jats:styled-content> in univariate analysis. In the multivariate analysis, the only two factors independently and inversely associated with <jats:styled-content style=\"fixed-case\">C<jats:sub>DFX<\/jats:sub><\/jats:styled-content> levels were time from last drug intake to blood sampling and ferritin levels (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.006). A significant inverse correlation (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.03) was observed between <jats:styled-content style=\"fixed-case\">C<jats:sub>DFX<\/jats:sub><\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">UGT<\/jats:styled-content>1A1*28 gene polymorphism, but only in patients with levels of lean body mass (<jats:styled-content style=\"fixed-case\">LBM<\/jats:styled-content>) below the median (<jats:italic>P<\/jats:italic> for interaction\u00a0=\u00a00.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results could indicate that a higher plasma <jats:styled-content style=\"fixed-case\">DFX<\/jats:styled-content> concentration could be associated with greater chelation efficacy. As a correlation between dose and <jats:styled-content style=\"fixed-case\">C<jats:sub>DFX<\/jats:sub><\/jats:styled-content> was not demonstrated, it seems useful to monitor the concentrations to optimize and determine the most appropriate dose for each patient. Interesting results emerged from the analysis of genetic and physical characteristics of patients: <jats:styled-content style=\"fixed-case\">LBM<\/jats:styled-content> was a borderline significant effect modifier of the relationship between <jats:styled-content style=\"fixed-case\">UGT<\/jats:styled-content>1A1 polymorphisms and <jats:styled-content style=\"fixed-case\">C<jats:sub>DFX<\/jats:sub><\/jats:styled-content>. Individual patient\u2010tailored dosing of <jats:styled-content style=\"fixed-case\">DFX<\/jats:styled-content> should help to improve iron chelation efficacy and to reduce dose\u2010dependent drug toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12419","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T07:47:39Z","timestamp":1406879259000},"page":"310-317","source":"Crossref","is-referenced-by-count":20,"title":["Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?"],"prefix":"10.1111","volume":"94","author":[{"given":"Francesca","family":"Mattioli","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Clinical Pharmacology and Toxicology Unit University of Genoa Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Puntoni","sequence":"additional","affiliation":[{"name":"Clinical Trial Unit Scientific Directorate E.O. Galliera Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Marini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Clinical Pharmacology and Toxicology Unit University of Genoa Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fucile","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Clinical Pharmacology and Toxicology Unit University of Genoa Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Milano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Clinical Pharmacology and Toxicology Unit University of Genoa Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Robbiano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Clinical Pharmacology and Toxicology Unit University of Genoa Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silverio","family":"Perrotta","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Second University of Naples Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Pinto","sequence":"additional","affiliation":[{"name":"SSD Ematologia \u2013 Centro della Microcitemia E.O. Galliera Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Clinical Pharmacology and Toxicology Unit University of Genoa Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Forni","sequence":"additional","affiliation":[{"name":"SSD Ematologia \u2013 Centro della Microcitemia E.O. Galliera Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.739"},{"key":"e_1_2_9_3_1","first-page":"CD007476","article-title":"Deferasirox for managing iron overload in people with thalassaemia","volume":"2","author":"Meerpohl JJ","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.030833"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007313327"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.022962"},{"key":"e_1_2_9_8_1","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once\u2010daily, orally\u2010administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2012.640674"},{"key":"e_1_2_9_10_1","volume-title":"ICH \u2013Gender considerations in the conduct of clinical trials","author":"European Medicines Agency (EMA)","year":"2005"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2006.0135"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2012.02.047"},{"key":"e_1_2_9_13_1","volume-title":"Research on obesity","author":"James WPT","year":"1976"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00079-2"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600810324"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040112"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181d8b37f"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01204.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.7.879"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511023331802"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2011.00754.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200053586064"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.12.030"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200202000-00018"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12419","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:36:55Z","timestamp":1696318615000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,17]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/ejh.12419"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12419","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,17]]}}}